Graham Capital Management’s Cytek Biosciences CTKB Stock Holding History

Graham Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-82,286	Closed	-$330K	–	1345
2025 Q1	$330K	Buy	82,286 +54,868	+200%	+$284K	0.01%	961
2024 Q4	$178K	Buy	27,418 +17,198	+168%	+$102K	﹤0.01%	1094
2024 Q3	$56.6K	Buy	+10,220	New	+$58K	﹤0.01%	1039
2024 Q2	–	Sell	-15,379	Closed	-$103K	–	1098
2024 Q1	$103K	Buy	+15,379	New	+$122K	﹤0.01%	972
2022 Q2	–	Sell	-19,884	Closed	-$214K	–	1046
2022 Q1	$214K	Buy	+19,884	New	+$269K	0.01%	817

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Graham Capital Management's CTKB Position: Q2 2025 in Review

Graham Capital Management sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 82,286 shares — an estimated $330K sold.

Graham Capital Management first reported a position in CTKB in Q1 2022 and held it in 5 quarters. The position peaked at $330K in Q1 2025. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

Graham Capital Management reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
Graham Capital Management sold 82,286 Cytek Biosciences shares in Q2 2025, an estimated $330K.
Graham Capital Management first reported a position in Cytek Biosciences in Q1 2022 and held it in 5 quarters.
Graham Capital Management's Cytek Biosciences position peaked at $330K in Q1 2025.
158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.